Target intelligence / Profile preview

Serotonin transporter, Norepinephrine transporter, Dopamine transporter

Molecular classification
Transporter, Solute carrier protein (SLC6 family), Sodium- and chloride-dependent transporter
01

Overview

Monoamine transporters—including the **serotonin transporter (SERT)**, **norepinephrine transporter (NET)**, and **dopamine transporter (DAT)**—are integral membrane proteins of the SLC6 family that mediate the high-affinity reuptake of their respective monoamine neurotransmitters from the synaptic cleft into the presynaptic neuron, thereby terminating neurotransmitter signaling and regulating synaptic monoamine levels[2][4][5][8]. Each transporter consists of 12 transmembrane helices and relies on sodium and chloride co-transport to drive neurotransmitter uptake against a concentration gradient[2][4][5][7][8]. Their modulation by drugs underlies the efficacy of many antidepressants, psychostimulants, and analgesics, while their dysfunction is implicated in psychiatric and neurological disorders[3][4][8].

Other names
5-HT transporterSERTNoradrenaline transporterNETDATdopamine active transporterMonoamine transportersMATs
02

Mechanism of action

Inhibition of neurotransmitter reuptake, increasing extracellular monoamine levels in the synaptic cleft\nCompetitive and noncompetitive inhibition\nSubstrate translocation and reverse transport (depending on the drug)\nModulation of transporter conformation

03

Biological functions

Neurotransmitter reuptakeTermination of synaptic signalingRegulation of neurotransmitter homeostasisControl of synaptic transmission intensity and duration
04

Disease associations

Major depressive disorderAnxiety disordersAttention-deficit/hyperactivity disorder (ADHD)Parkinson’s diseaseSubstance use disorders (addiction)Chronic painOther neuropsychiatric and neurodegenerative diseases
05

Safety considerations

Risk of serotonin syndrome (with SERT inhibitors)Cardiovascular side effects (increased blood pressure and heart rate with NET/DAT inhibitors)Abuse potential (especially with DAT inhibitors, e.g., cocaine)Withdrawal and dependencePsychiatric adverse effects (e.g., mania induction, anxiety exacerbation)
06

Interacting drugs

Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, citalopram)

7 more in the full profile.

07

Biomarkers

Monoamine metabolite levels in plasma/CSFNeuroimaging of transporter density (PET/SPECT ligands, e.g., [^123I]β-CIT)Platelet SERT function (for peripheral studies)

Beyond the preview

Go deeper on Serotonin transporter, Norepinephrine transporter, Dopamine transporter.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin transporter, Norepinephrine transporter, Dopamine transporter.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call